Bictegravir/lenacapavir (Bixlenvo) vs VH4004280 (VH-280)

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

HIV

Shared mechanism: HIV capsid · full HIV pipeline

Bictegravir/lenacapavir (Bixlenvo)

Marketed by Gilead Sciences

Approved in HIVsmall molecule
Partial signal

NCT05502341 · Phase 2/3 · active, not recruiting

This was a randomized, active-controlled trial in 557 people in its Phase 3 part, but it was open-label, so participants and investigators knew which treatment each person received. Its primary endpoint, the proportion with detectable HIV-1 RNA at week 48, is an objective laboratory measure, and bictegravir/lenacapavir met the non-inferiority goal against continued complex regimens.

Next expected readout: July 2028 · NCT07908446 (registry estimate)

Reported efficacy

Phase 2: Percentage of Participants With Human Immunodeficiency Virus-1 Ribonucleic Acid (HIV-1 RNA) ≥ 50 Copies/mL at Week 24 as Determined by the United States Food and Drug Administration (US FDA) Defined Snapshot Algorithm; Phase 3: Percentages of Participants With HIV-1 RNA ≥ 50 Copies/mL at Week 48 as Determined by the US FDA-defined Snapshot Algorithm: Phase 3 primary, HIV-1 RNA >=50 copies/mL at week 48 (FDA snapshot): BIC/LEN 0.8% (n=371) vs stable baseline regimen 1.1% (n=186), difference -0.3% (95.002% CI -2.3% to 1.8%); Gilead states the non-inferiority criterion was met. Phase 2 week 24: 0% and 1.9% vs 0% (CT.gov posted results). (met)

Result source: NCT05502341

VH4004280 (VH-280)

Developed by ViiV Healthcare

Phase 2 in HIVsmall molecule
Partial signal

NCT06039579 · Phase 2 · completed

This is a randomized, double-blind, placebo-controlled parallel-group trial, but the primary endpoint is a surrogate biomarker (plasma HIV-1 RNA) rather than a hard clinical/endoscopic outcome, and the sample size is small (only 3-7 participants per arm), which limits precision and power. Although the posted results show large antiviral effects in the active arms relative to placebo, no statistical significance testing or confidence intervals are provided, so the primary comparison cannot be confirmed as met.

Reported efficacy

Monotherapy, VH4004280: Maximum Change From Baseline (Day 1) in Plasma HIV-1 Ribonucleic Acid (RNA) log10 (From Baseline (Day 1) and up to Day 11); Monotherapy, VH4011499: Maximum Change From Baseline (Day 1) in Plasma HIV-1 RNA log10 (From Baseline (Day 1) and up to Day 11): Monotherapy, VH4004280: Maximum Change From Baseline (Day 1) in Plasma HIV-1 Ribonucleic Acid (RNA) log10 (From Baseline (Day 1) and up to Day 11): Part 1a: VH4004280 Dose Level 1 — Baseline (Day 1): 5.004 log10 c/mL (Standard Deviation 0.4592); Maximum change compared to Baseline (Day 1): -1.056 log10 c/mL (Standard Deviation 0.4567) | Part 1a: VH4004280 Dose Level 2 — Baseline (Day 1): 4.923 log10 c/mL (Standard Deviation 0.5428); Maximum change compared to Baseline (Day 1): -1.391 log10 c/mL (Standard Deviation 0.6986) | Part 2a: VH4004280 Pre-specified Dose — Baseline (Day 1): 4.866 log10 c/mL (Standard Deviation 0.7696); Maximum change compared to Baseline (Day 1): -1.983 log10 c/mL (Standard Deviation 0.2171) vs Matching Placebo for VH4004280 — Baseline (Day 1): 4.636 log10 c/mL (Standard Deviation 0.6641); Maximum change compared to Baseline (Day 1): -0.07 log10 c/mL (Standard Deviation 0.0574) (unclear)

Result source: NCT06039579

Results for HIV

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointBictegravir/​lenacapavir (Bixlenvo)VH4004280 (VH-280)
HIV-1 RNA below 50 copies/mL (week 48)—Trial running · NCT06532656—Not reported
HIV-1 RNA 50 copies/mL or more (week 48)—Trial running · NCT06532656—Not reported
CD4 count, change (week 48)—Trial running · NCT06532656—Not reported

HIV-1 RNA below 50 copies/mL (week 48)

Bictegravir/​lenacapavir (Bixlenvo)
—Trial running · NCT06532656
VH4004280 (VH-280)
—Not reported

HIV-1 RNA 50 copies/mL or more (week 48)

Bictegravir/​lenacapavir (Bixlenvo)
—Trial running · NCT06532656
VH4004280 (VH-280)
—Not reported

CD4 count, change (week 48)

Bictegravir/​lenacapavir (Bixlenvo)
—Trial running · NCT06532656
VH4004280 (VH-280)
—Not reported
  1. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  2. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.

Reviewed results are available, but are not yet structured for this comparison. These sourced summaries are shown separately from the aligned rows.

Bictegravir/lenacapavir (Bixlenvo)
Phase 3 primary, HIV-1 RNA >=50 copies/mL at week 48 (FDA snapshot): BIC/LEN 0.8% (n=371) vs stable baseline regimen 1.1% (n=186), difference -0.3% (95.002% CI -2.3% to 1.8%); Gilead states the non-inferiority criterion was met. Phase 2 week 24: 0% and 1.9% vs 0% (CT.gov posted results). NCT05502341 · Phase 2/3 · design grade: moderate · publication or press release

Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.

safety

Coverage. Bictegravir/lenacapavir (Bixlenvo): 0 of 4 rows · VH4004280 (VH-280): 3 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.

Reported metricVH4004280 (VH-280)
Dropout rate
0%Dose Level 1a
NCT06039579 · Phase 2 · combination · HIV · phase 2
show 16 more results
—Dose Level 1
NCT06039579 · Phase 2 · combination · HIV · phase 2
—Dose Level 1
NCT06039579 · Phase 2 · monotherapy · HIV · phase 2
0%Dose Level 2
NCT06039579 · Phase 2 · combination · HIV · phase 2
—Dose Level 2
NCT06039579 · Phase 2 · combination · HIV · phase 2
0%Pre-specified Dose
NCT06039579 · Phase 2 · combination · HIV · phase 2
—Pre-specified Dose
NCT06039579 · Phase 2 · combination · HIV · phase 2
—Pre-specified Dose
NCT06039579 · Phase 2 · monotherapy · HIV · phase 2
0%900 mg
NCT05163522 · Phase 1 · monotherapy
0%450 mg
NCT05163522 · Phase 1 · monotherapy
0%450 mg
NCT05163522 · Phase 1 · monotherapy
0%350 mg
NCT05163522 · Phase 1 · monotherapy
0%250 mg + Midazolam
NCT05163522 · Phase 1 · combination
0%150 mg
NCT05163522 · Phase 1 · monotherapy
0%100 mg
NCT05163522 · Phase 1 · monotherapy
14.3%50 mg
NCT05163522 · Phase 1 · monotherapy
0%10 mg
NCT05163522 · Phase 1 · monotherapy
Discontinued due to AEs
—Dose Level 1a
NCT06039579 · Phase 2 · combination · HIV · phase 2
show 16 more results
—Dose Level 1
NCT06039579 · Phase 2 · combination · HIV · phase 2
—Dose Level 1
NCT06039579 · Phase 2 · monotherapy · HIV · phase 2
—Dose Level 2
NCT06039579 · Phase 2 · combination · HIV · phase 2
—Dose Level 2
NCT06039579 · Phase 2 · combination · HIV · phase 2
—Pre-specified Dose
NCT06039579 · Phase 2 · combination · HIV · phase 2
—Pre-specified Dose
NCT06039579 · Phase 2 · combination · HIV · phase 2
—Pre-specified Dose
NCT06039579 · Phase 2 · monotherapy · HIV · phase 2
—900 mg
NCT05163522 · Phase 1 · monotherapy
—450 mg
NCT05163522 · Phase 1 · monotherapy
—450 mg
NCT05163522 · Phase 1 · monotherapy
—350 mg
NCT05163522 · Phase 1 · monotherapy
—250 mg + Midazolam
NCT05163522 · Phase 1 · combination
—150 mg
NCT05163522 · Phase 1 · monotherapy
—100 mg
NCT05163522 · Phase 1 · monotherapy
—50 mg
NCT05163522 · Phase 1 · monotherapy
—10 mg
NCT05163522 · Phase 1 · monotherapy
Serious AEs
—Dose Level 1a
NCT06039579 · Phase 2 · combination · HIV · phase 2
show 16 more results
0%Dose Level 1
NCT06039579 · Phase 2 · combination · HIV · phase 2
0%Dose Level 1
NCT06039579 · Phase 2 · monotherapy · HIV · phase 2
0%Dose Level 2
NCT06039579 · Phase 2 · combination · HIV · phase 2
0%Dose Level 2
NCT06039579 · Phase 2 · combination · HIV · phase 2
—Pre-specified Dose
NCT06039579 · Phase 2 · combination · HIV · phase 2
0%Pre-specified Dose
NCT06039579 · Phase 2 · combination · HIV · phase 2
0%Pre-specified Dose
NCT06039579 · Phase 2 · monotherapy · HIV · phase 2
0%900 mg
NCT05163522 · Phase 1 · monotherapy
0%450 mg
NCT05163522 · Phase 1 · monotherapy
0%450 mg
NCT05163522 · Phase 1 · monotherapy
0%350 mg
NCT05163522 · Phase 1 · monotherapy
0%250 mg + Midazolam
NCT05163522 · Phase 1 · combination
0%150 mg
NCT05163522 · Phase 1 · monotherapy
0%100 mg
NCT05163522 · Phase 1 · monotherapy
0%50 mg
NCT05163522 · Phase 1 · monotherapy
0%10 mg
NCT05163522 · Phase 1 · monotherapy
Most frequent reported AEs
Dose Level 1a
transaminases increased 16.7% (placebo 0%)
alanine aminotransferase increased 0% (placebo 0%)
arthralgia 0% (placebo 0%)
NCT06039579 · Phase 2 · combination · HIV · phase 2
show 14 more results
Dose Level 1
headache 16.7% (placebo 0%)
periodontitis 16.7% (placebo 0%)
rhinitis allergic 16.7% (placebo 0%)
NCT06039579 · Phase 2 · monotherapy · HIV · phase 2
Dose Level 2
blood creatinine increased 33.3% (placebo 0%)
pyrexia 16.7% (placebo 0%)
thrombocytopenia 16.7% (placebo 0%)
NCT06039579 · Phase 2 · combination · HIV · phase 2
Dose Level 2
blood creatinine increased 33.3% (placebo 0%)
hypertriglyceridaemia 33.3% (placebo 0%)
cough 16.7% (placebo 0%)
NCT06039579 · Phase 2 · combination · HIV · phase 2
Pre-specified Dose
cough 16.7% (placebo 0%)
pharyngitis 16.7% (placebo 0%)
rhinitis 16.7% (placebo 0%)
NCT06039579 · Phase 2 · combination · HIV · phase 2
Pre-specified Dose
alanine aminotransferase increased 16.7% (placebo 0%)
dengue fever 16.7% (placebo 0%)
urticaria 16.7% (placebo 0%)
NCT06039579 · Phase 2 · monotherapy · HIV · phase 2
900 mg
headache 16.7% (placebo 0%)
abdominal discomfort 0% (placebo 0%)
alanine aminotransferase increased 0% (placebo 10%)
NCT05163522 · Phase 1 · monotherapy
450 mg
abdominal discomfort 0% (placebo 0%)
alanine aminotransferase increased 0% (placebo 10%)
amylase increased 0% (placebo 0%)
NCT05163522 · Phase 1 · monotherapy
450 mg
alanine aminotransferase increased 16.7% (placebo 10%)
amylase increased 16.7% (placebo 0%)
aspartate aminotransferase increased 16.7% (placebo 10%)
NCT05163522 · Phase 1 · monotherapy
350 mg
alanine aminotransferase increased 16.7% (placebo 10%)
aspartate aminotransferase increased 16.7% (placebo 10%)
bile acids increased 16.7% (placebo 0%)
NCT05163522 · Phase 1 · monotherapy
250 mg + Midazolam
fatigue 62.5% (placebo 0%)
blood creatine phosphokinase increased 25% (placebo 0%)
low density lipoprotein increased 25% (placebo 0%)
NCT05163522 · Phase 1 · combination
150 mg
abdominal discomfort 0% (placebo 0%)
alanine aminotransferase increased 0% (placebo 10%)
amylase increased 0% (placebo 0%)
NCT05163522 · Phase 1 · monotherapy
100 mg
dyslipidaemia 33.3% (placebo 0%)
bile acids increased 16.7% (placebo 0%)
blood bilirubin increased 16.7% (placebo 0%)
NCT05163522 · Phase 1 · monotherapy
50 mg
abdominal discomfort 28.6% (placebo 0%)
diarrhoea 28.6% (placebo 0%)
body temperature increased 14.3% (placebo 0%)
NCT05163522 · Phase 1 · monotherapy
10 mg
chapped lips 16.7% (placebo 0%)
dermatitis contact 16.7% (placebo 10%)
dry mouth 16.7% (placebo 0%)
NCT05163522 · Phase 1 · monotherapy

Notes

  1. aPopulation comparability has not been reviewed for 9 of these studies.

Reported by one asset only

Endpoints only one of the selected assets measured, so there is nothing to compare them against.

VH4004280 (VH-280)

HIV-1 RNA -1.056 vs -0.07 placebo logDose Level 1
absolute change · log
Maximum change compared to Baseline (Day 1)
NCT06039579 · Phase 2 · combination · HIV · phase 2
show 2 more results
-1.391 vs -0.07 placebo logDose Level 2
Maximum change compared to Baseline (Day 1)
NCT06039579 · Phase 2 · combination · HIV · phase 2
-1.983 vs -0.07 placebo logPre-specified Dose
Maximum change compared to Baseline (Day 1)
NCT06039579 · Phase 2 · combination · HIV · phase 2
HIV-1 RNA -0.941 log @ 1.57wkDose Level 1
absolute change · log
No placebo or comparator arm
NCT06039579 · Phase 2 · combination · HIV · phase 2
show 2 more results
-1.322 log @ 1.57wkDose Level 2
NCT06039579 · Phase 2 · combination · HIV · phase 2
-1.939 log @ 1.57wkPre-specified Dose
NCT06039579 · Phase 2 · combination · HIV · phase 2

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Bictegravir/lenacapavir (Bixlenvo)'s landscape · VH4004280 (VH-280)'s landscape